Activation of key cancer pathways was found to be associated with specific genomic contexts including mutation of cell cycle genes, TERT expression, tumor mutation burden, and non-triple wt status of tumors and thus points to the need for development of novel drug classes to potentially inhibit activated pathways. Here, TERT is linked to neoplasm.